SS 40 - Evolving Paradigms in High-Risk Breast Cancer: Optimization and Integration of Treatment Modalities Across the Disease Continuum

Presentations

• 03:45pm - 03:55pm ET

  Neoadjuvant Radiotherapy in Breast Cancer: A Study on the Optimal Sequencing of Radiation in Breast Cancer (NeoORB)

  Speaker: Rishi Nair, MBBS - AIIMS Jodhpur, Jodhpur
• 03:55pm - 04:05pm ET

  Toxicity Results from TBCRC-053 (P-RAD): A Randomized Trial of No, Low or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive HER2-Negative Breast Cancer

  Speaker: Elitza Koutleva, MD, MBA - University of North Carolina at Chapel Hill, Chapel Hill
• 04:05pm - 04:15pm ET

  Association of Baseline Cardiac Risk Factors, Patient and Treatment Variables with Cardiac Adverse Events (AE) for Early-Stage Breast Cancer Patients on NRG Oncology RTOG 1005 (NRG/R1005) Clinical Trial

  Speaker: Julia White, MD, FASTRO - University of Kansas Cancer Center, Kansas City
• 04:15pm - 04:25pm ET

  Simultaneous Integrated Boost in Hypofractionated Regional Lymph Node Irradiotherapy for cN3 Breast Cancer: Preliminary Report of a Prospective Phase 2 Single-Arm Trial

  Speaker: Yutong Tan, MD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical , Shenzhen
• 04:25pm - 04:35pm ET

  Phase I/II Study of Concurrent Abemaciclib and Adjuvant Radiotherapy in Patients with HR+, HER2-, High-Risk Breast Cancer

  Speaker: Yuchun Song, MD - Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
• 04:35pm - 04:45pm ET

  Phase 1b Trial of Berzosertib as a Radiosensitizer in the Post-Neoadjuvant Treatment of Chemotherapy-Resistant HER2-Negative Breast Cancer

  Speaker: Robert Mutter, MD - Mayo Clinic, Rochester
• 04:45pm - 04:55pm ET

  Discussant

  Speaker: Wendy Woodward, MD, PhD, FASTRO - MD Anderson Cancer Center, Houston